In case you missed it: Last week we announced our second quarter financial results. Click here for the full announcement: https://lnkd.in/drD3A4Yb #PressRelease #QuarterlyReport #BusinessUpdate #CompanyNews #BiotechNews #Biotech #Investors #Media
Immatics
Biotechnologieforschung
Delivering the Power of T Cells to Cancer Patients
Info
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer. Read more about Immatics on our homepage: https://immatics.com/ Find us also on: Twitter: https://twitter.com/immatics Instagram: https://www.instagram.com/immatics/ YouTube: https://www.youtube.com/channel/UCv7uTpsGXvSNzwSX_xOtYSA Legal notice: https://immatics.com/imprint/
- Website
-
http://www.immatics.com
Externer Link zu Immatics
- Branche
- Biotechnologieforschung
- Größe
- 201–500 Beschäftigte
- Hauptsitz
- Tuebingen
- Kunst
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Gegründet
- 2000
- Spezialgebiete
- Discovery of HLA-restricted tumor-associated peptides as cancer targets, Biomarkers, Immunomonitoring, Peptidomics & mass spectrometry, Standardized PBMC collection, Bioinformatics, Immunology, TCR Discovery, Bispecific Development, TCR-based Immunotherapies, Adoptive Cell Therapy, TCR Bispecifics und Cancer
Orte
-
Primär
Paul-Ehrlich-Str. 15
Tuebingen, 72076, DE
-
Machtlfinger Straße 11
Munich, Bavaria 81379, DE
-
2130 W Holcombe Blvd
Suite 900
Houston, Texas 77030, US
Beschäftigte von Immatics
Aktualisierungen
-
Today we reported our Q2 2024 financial results and provided a corporate update. Click here for the full announcement: https://lnkd.in/drD3A4Yb #PressRelease #QuarterlyReport #BusinessUpdate #CompanyNews #BiotechNews #Biotech #Investors #Media
-
A few weeks ago, we had the pleasure of welcoming Philip Hemme to Immatics‘ office in Munich to record an episode for his podcast, Flot.bio, with our CEO, Harpreet Singh. The conversation was dynamic, engaging and insightful. Stay tuned for the final episode! #PodcastEpisode #BiotechTalk #PharmaPodcast #ListenToThis
In 2000, Harpreet co-founded a venture after his PhD. Now, Immatics is one of the 15 most valuable European biotechs. Great to meet him in person for the first time and to record an episode while I was in Munich 🇩🇪 We talked about the field of PRAME receptors, TCR therapeutics and Cell Therapy at large. We also spoke about the combination with mRNA therapeutics and his upbringing in a Sikh family in Germany. Full episode will be online first week of September ⏰
-
Today we announced the appointment of Alise Reicin, MD to our Board of Directors. Dr. Reicin is an experienced and expert pharmaceutical industry executive and leader who has led the development of multiple important new therapies, including Keytruda®. She brings extensive knowledge in early- and late-stage clinical development and a legacy of approved drugs in diverse therapeutic areas. We are delighted to welcome her to the Board of Directors as we advance our pipeline of novel TCR-based cell therapy and bispecific product candidates into the next phase of development. For more information, read the full press release here: https://lnkd.in/dy3aXN32 #leadership #growth #healthcare #biotech #innovation #BoardOfDirectors #CorporateGovernance #WomenOnBoards
-
“Great science translates to great patient outcomes.” This theme kicked off Immatics’ Science Day 2024 at the company headquarters in Tübingen, Germany. The event brought together Immatics’ talented scientists for a day of presentations on ongoing research and projects. Science Day also gave the team an opportunity to form and strengthen connections between research and development departments across the organization. From sessions about innovation in manufacturing to conversations about the application of artificial intelligence in drug development, Science Day 2024 showcased the hard work Immatics’ scientists are doing to pioneer novel cancer immunotherapies. Through dedication, collaboration and innovation, together we can improve the lives of cancer patients. #healthcare #biotech #science #research #cancer
-
Today we announced that the first proof-of-concept clinical data for our next-generation, half-life extended TCR Bispecific molecule, TCER® IMA401 (MAGEA4/8), will be presented during an oral presentation at the ESMO - European Society for Medical Oncology Congress on Monday, September 16, 2024 at 11:25 CEST. For more details on the presentation, access the full press release here: https://lnkd.in/erHUuX_c #ESMO24 #biotech #cancer #oncology #clinicaldata
-
Big congratulations are in order for our Immatics managers! We believe that investing in our employees’ growth and development is essential for their success. The New & Emerging Leaders program at Houston Community College consisted of 20 employees from different roles across our organization. For 5 months, our new and emerging leaders acquired skills to navigate and manage organizational challenges and studied the art of planning and executing projects to ensure success. We are proud that our employees carry with them these new skills and fresh perspectives to continue to lead and inspire others to reach new heights! #Innovation #EmergingLeaders #RealWorldEducation #ProfessionalDevelopment #CareerGrowth
-
Our CEO, Harpreet Singh, will be a keynote speaker at the upcoming Curious 2024 Future Insight e.V. Conference. His presentation, “Developing living drugs against cancer: TCR-T cell therapies,” will take place tomorrow, July 10 from 3:00 - 3:30 pm CET. For more information about the conference, click here: curiousfutureinsight.org #unitedbyscience #curious2024 #celltherapy #biotech #innovation #lifescience #cancer
-
Despite a forecast of rain, the clouds cleared just in time for the Immatics summer party. 🌍 Immatics employees from all across Germany, and some from our site in Houston, recently gathered at the facility in Tübingen for a fantastic evening of fun, food and festivities. 🎉 From playing giant games and solving riddles during a treasure hunt to being captivated by magic tricks, it was great to have the team all together to celebrate our hard work, the new Campus Sternwarte facility and the summer season. We can’t wait for our next team get-together! #TeamBuilding #Biotech #CorporateEvents #WorkHardPlayHard #TeamCelebration #EmployeeAppreciation
-
Last month, the European Medical Students’ Association (EMSA) hosted an event in Tübingen, Germany. Andrea Mayer-Mokler, Vice President Global Head of Clinical Sciences at Immatics, was invited to present the company to a group of medical students. During her presentation, Andrea shared Immatics’ story and emphasized how physicians are instrumental in moving innovative treatments from bench to bedside and can facilitate patient access to clinical trials. Thank you, EMSA, for this opportunity to connect with future leaders in the medical field. Together, we can make a difference in the lives of cancer patients. #biotech #EuropeanMedicalOrganizations #clinicaltrials #cancer